Publication
Circulating tumor DNA-guided de-escalation or escalation of adjuvant therapy in high-risk stage II and stage III colon cancer: the phase 2 PEGASUS trial.
Silvia Marsoni, Clara Montagut, Filippo Pietrantonio, Andrea Sartore-Bianchi, Luca Lazzari, Francesca Bergamo, Maria Giulia Zampino, Noelia Tarazona, Mario Mandalà, Stefano Tamberi, Elena Elez, Cristina Santos Vivas, Paolo Luraghi, Michele Prisciandaro, Federica Tosi, Davide Ciardiello, Joana Vidal, Victor Seguì, Michele Palazzo, Giulia Maddalena, Katia Bencardino, Ida Taglialatela, Marta Guix, Eliana Rulli, Valentina Vettore, Federica Morano, Claudio Isella, Giovanni Crisafulli, Giorgio Patelli, Enzo Medico, Alberto Bardelli, Andrés Cervantes, Valter Torri, Josep Tabernero, Salvatore Siena, Sara Lonardi
- Source
- PubMed
- Retrieved
- Sep 19, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260919-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Oxaliplatin-fluoropyrimidine combinations are standard adjuvant therapy after radical resection of high-risk stage II and stage III colon cancer but expose many patients to toxicity while failing to prevent relapse in others. PEGASUS was a multicenter, single-arm, phase 2 trial evaluating the…
Read on PubMedLinked entities
Linked entities (3)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 2
- trialNCT00646607registry_reference1.00
- trialNCT04259944registry_reference1.00
Candidate 1
- cancerMalignant Colon Neoplasmdictionary0.60
Registered trialsNCT00646607NCT04259944
Curated evidence
Evidence citing this paper (0)
Data not yet available